C
Constadina Arvanitis
Researcher at Northwestern University
Publications - 19
Citations - 2228
Constadina Arvanitis is an academic researcher from Northwestern University. The author has contributed to research in topics: Oncogene & Carcinogenesis. The author has an hindex of 12, co-authored 17 publications receiving 2066 citations. Previous affiliations of Constadina Arvanitis include Stanford University & Children's Memorial Hospital.
Papers
More filters
Journal ArticleDOI
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Catherine M. Shachaf,Andrew M. Kopelman,Constadina Arvanitis,Asa Karlsson,Shelly Beer,Stefanie Mandl,Michael Bachmann,Alexander D. Borowsky,Boris H. Ruebner,Robert D. Cardiff,Qiwei Yang,J. Michael Bishop,Christopher H. Contag,Dean W. Felsher +13 more
TL;DR: It is reported that inactivation of the MYC oncogene is sufficient to induce sustained regression of invasive liver cancers and how oncogenic inactivation may reverse tumorigenesis in the most clinically difficult cancers is shown.
Journal ArticleDOI
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Meenakshi Jain,Constadina Arvanitis,Kenneth Chu,William C. Dewey,Edith A. Leonhardt,Maxine Trinh,Christopher D. Sundberg,J. Michael Bishop,Dean W. Felsher +8 more
TL;DR: It is demonstrated that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes, raising the possibility that transient in activation ofMYC may be an effective therapy for certain cancers.
Journal ArticleDOI
Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
C. S. Pichot,Sean M. Hartig,Ling Xia,Constadina Arvanitis,D. Monisvais,Francis Y. Lee,Jeffrey A. Frost,Seth J. Corey +7 more
TL;DR: Combination treatment with doxorubicin resulted in synergistic growth inhibition in all cell lines and blocked the migration and invasion of the highly metastatic, triple-negative MDA-MB-231 cell line, warrants the re-evaluation of dasatinib as an effective agent in multi-drug regimens for the treatment of invasive breast cancers.
Journal ArticleDOI
Conditional transgenic models define how MYC initiates and maintains tumorigenesis.
TL;DR: Conditional transgenic mouse model systems are tractable methods to precisely dissect how and when the inactivation of MYC might be effective in the treatment for human cancer.
Journal ArticleDOI
Developmental context determines latency of MYC-induced tumorigenesis.
Shelly Beer,Anders Zetterberg,Rebecca A. Ihrie,Ryan A McTaggart,Qiwei Yang,Nicole Bradon,Constadina Arvanitis,Laura D. Attardi,Sandy Feng,Boris H. Ruebner,Robert D. Cardiff,Dean W. Felsher +11 more
TL;DR: The tetracycline regulatory system is used to generate transgenic mice in which the expression of a c-MYC human transgene can be conditionally regulated in murine hepatocytes and it is found that apoptosis is not a barrier to MYC inducing tumorigenesis.